应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06185 康希诺生物
休市中 11-20 16:08:29
21.140
-0.860
-3.91%
最高
21.500
最低
20.920
成交量
182.78万
今开
21.500
昨收
22.000
日振幅
2.64%
总市值
52.23亿
流通市值
28.05亿
总股本
2.47亿
成交额
3,857万
换手率
1.38%
流通股本
1.33亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
异动解读|康希诺生物盘中下跌4.09%,Td5cp扩龄临床获批后资金继续观望
行情直击 · 11-20 09:56
异动解读|康希诺生物盘中下跌4.09%,Td5cp扩龄临床获批后资金继续观望
异动解读|康希诺生物盘中下跌4.03%,Td5cp疫苗获批扩龄临床后资金继续观望
行情直击 · 11-17
异动解读|康希诺生物盘中下跌4.03%,Td5cp疫苗获批扩龄临床后资金继续观望
康希诺生物(06185)发布公告:2026年三季报说明会定档11月25日
公告速递 · 11-16
康希诺生物(06185)发布公告:2026年三季报说明会定档11月25日
康希诺生物(06185.HK):Td5cp在中国获得4至5周岁人群中开展临床试验的批准
智通财经 · 11-16
康希诺生物(06185.HK):Td5cp在中国获得4至5周岁人群中开展临床试验的批准
康希诺生物(06185)Td5cp疫苗获准在4至5岁人群开展临床试验
公告速递 · 11-16
康希诺生物(06185)Td5cp疫苗获准在4至5岁人群开展临床试验
异动解读|康希诺生物盘中下跌4.02%,股本稳定与保荐代表人变更未改观望情绪
行情直击 · 11-13
异动解读|康希诺生物盘中下跌4.02%,股本稳定与保荐代表人变更未改观望情绪
【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注
金吾财讯 · 11-13
【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注
【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存
金吾财讯 · 11-06
【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存
异动解读|康希诺生物盘中上涨5.42%,生物科技板块走强叠加三季报增长支撑情绪
行情直击 · 11-05
异动解读|康希诺生物盘中上涨5.42%,生物科技板块走强叠加三季报增长支撑情绪
异动解读|康希诺生物盘中上涨5.06%,生物科技板块走强叠加三季报增长支撑情绪
行情直击 · 11-04
异动解读|康希诺生物盘中上涨5.06%,生物科技板块走强叠加三季报增长支撑情绪
康希诺生物更新10月股份变动月报表,股本维持稳定
公告速递 · 11-03
康希诺生物更新10月股份变动月报表,股本维持稳定
异动解读|康希诺生物盘中下跌5.06%,保荐代表人变更叠加板块走弱
行情直击 · 11-03
异动解读|康希诺生物盘中下跌5.06%,保荐代表人变更叠加板块走弱
康希诺生物变更持续督导保荐代表人
公告速递 · 11-02
康希诺生物变更持续督导保荐代表人
异动解读|康希诺生物盘中上涨6.1%,前三季度营收与净利双增提振情绪
行情直击 · 10-28
异动解读|康希诺生物盘中上涨6.1%,前三季度营收与净利双增提振情绪
康希诺生物首批限制性股票归属81.13万股 前三季度计提减值及递延税资产共影响净利3303万元
公告速递 · 10-27
康希诺生物首批限制性股票归属81.13万股 前三季度计提减值及递延税资产共影响净利3303万元
康希诺生物(06185)发布三季报:前三季度营收8.82亿元 同比增27.40%
公告速递 · 10-27
康希诺生物(06185)发布三季报:前三季度营收8.82亿元 同比增27.40%
康希诺生物(06185.HK)前三季度归母净利润1629.13万元 同比增长12.82%
智通财经 · 10-27
康希诺生物(06185.HK)前三季度归母净利润1629.13万元 同比增长12.82%
康希诺生物前三季度业绩增长:多产品商业化提速,平台化创新打开成长空间
格隆汇 · 10-27
康希诺生物前三季度业绩增长:多产品商业化提速,平台化创新打开成长空间
异动解读|康希诺生物盘中下跌5.1%,莫得纳癌症疫苗数据扰动mRNA概念情绪
行情直击 · 10-27
异动解读|康希诺生物盘中下跌5.1%,莫得纳癌症疫苗数据扰动mRNA概念情绪
港股异动 | 康希诺生物跌逾5%,莫得纳癌症疫苗试验数据泄露未达市场高预期
智通财经 · 10-23
港股异动 | 康希诺生物跌逾5%,莫得纳癌症疫苗试验数据泄露未达市场高预期
公司概况
公司名称:
康希诺生物
所属市场:
SEHK
上市日期:
--
主营业务:
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
发行价格:
--
{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":21.14,"timestamp":1795162109007,"preClose":22,"halted":0,"volume":1827800,"delay":0,"changeRate":-0.039090909090909065,"floatShares":132670900,"shares":247043801,"eps":0.12901040850236697,"marketStatus":"休市中","change":-0.86,"latestTime":"11-20 16:08:29","open":21.5,"high":21.5,"low":20.92,"amount":38572920,"amplitude":0.026364,"askPrice":21.14,"askSize":5000,"bidPrice":21.06,"bidSize":800,"shortable":3,"etf":0,"ttmEps":0.14088757583785308,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":22,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":0.8078504072706607,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":55.1,"timestamp":1795158000000,"preClose":58.4,"halted":0,"volume":3661500,"delay":0,"premium":"-67.29"}},"requestUrl":"/m/hq/s/06185/wiki","defaultTab":"wiki","newsList":[{"id":"1137419257","title":"异动解读|康希诺生物盘中下跌4.09%,Td5cp扩龄临床获批后资金继续观望","url":"https://stock-news.laohu8.com/highlight/detail?id=1137419257","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137419257?lang=zh_cn&edition=full","pubTime":"2026-11-20 09:56","pubTimestamp":1795139784,"startTime":"0","endTime":"0","summary":"11月20日,康希诺生物盘中下跌4.09%,报21.06港元,成交额704.34万港元。近期公司披露,自主研发的吸附无细胞百白破联合疫苗Td5cp已获批在4至5周岁人群中开展临床试验,拟将6岁加强免疫年龄扩展至4至6岁。该进展显示产品管线持续推进,但仍处于临床试验获批阶段,短期业绩贡献仍待后续研发及商业化进展验证,市场资金表现偏谨慎。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物下跌,Td5cp扩龄获批后资金观望","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184780591","title":"异动解读|康希诺生物盘中下跌4.03%,Td5cp疫苗获批扩龄临床后资金继续观望","url":"https://stock-news.laohu8.com/highlight/detail?id=1184780591","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184780591?lang=zh_cn&edition=full","pubTime":"2026-11-17 14:35","pubTimestamp":1794897321,"startTime":"0","endTime":"0","summary":"11月17日,康希诺生物盘中下跌4.03%,报22.4港元,成交额3390.07万港元。消息面上,公司日前公告称,自主研发的吸附无细胞百白破联合疫苗Td5cp已获批在4至5周岁人群中开展临床试验,拟将6岁加强免疫年龄扩展至4至6岁。该产品采用降低抗原含量的Tdap思路,意在填补学龄前加强免疫窗口并快速恢复抗体保护水平;但本次仍属临床试验获批阶段,短期对业绩贡献尚待后续研发进展验证。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物走低,疫苗获批扩龄临床引关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111675484","title":"康希诺生物(06185)发布公告:2026年三季报说明会定档11月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=1111675484","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111675484?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:15","pubTimestamp":1794824136,"startTime":"0","endTime":"0","summary":"本次说明会将由公司董事长兼总经理宇学峰、董事会秘书崔进及代财务负责人刘明出席,围绕公司2026年第三季度经营成果和财务指标与投资者进行互动交流。在信息披露允许的范围内,公司将就投资者普遍关注的问题进行解答。说明会结束后,投资者可在上证路演中心查看会议回放及主要内容。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683069043","title":"康希诺生物(06185.HK):Td5cp在中国获得4至5周岁人群中开展临床试验的批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2683069043","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683069043?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:05","pubTimestamp":1794823551,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","06185","BK1191","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166287668","title":"康希诺生物(06185)Td5cp疫苗获准在4至5岁人群开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1166287668","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166287668?lang=zh_cn&edition=full","pubTime":"2026-11-16 18:05","pubTimestamp":1794823529,"startTime":"0","endTime":"0","summary":"2026年11月16日,康希诺生物股份公司发布自愿公告称,其自主研发的吸附无细胞百(五组分)白破联合疫苗Td5cp已获国家药品监督管理局批准,可在4至5岁人群中开展相关临床试验。国际上普遍采用抗原含量降低的Tdap疫苗自4岁起进行加强接种,以降低不良反应风险。此次临床试验申请拟将Td5cp的6岁加强免疫年龄扩展至4至6岁,以激发免疫记忆,使抗体水平迅速回升至有效保护范围。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191881613","title":"异动解读|康希诺生物盘中下跌4.02%,股本稳定与保荐代表人变更未改观望情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1191881613","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191881613?lang=zh_cn&edition=full","pubTime":"2026-11-13 10:15","pubTimestamp":1794536159,"startTime":"0","endTime":"0","summary":"11月13日,康希诺生物盘中下跌4.02%,报24.82港元,成交额3045.23万港元。近阶段公司披露的新增公开信息主要包括:10月股份变动月报显示,H股与A股数量均与上月一致,报告期内无新增发行、回购或注销;同时,公司完成持续督导保荐代表人变更,由王天祺接替徐峰林,与焦延延共同履职。此前公司三季报显示,前三季度实现营收8.82亿元,同比增长27.40%,归母净利润1629.13万元,同比增长12.82%。当前股价回落,公开消息面上未见更强新增催化,市场仍在消化既有业绩与行业情绪变化。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物盘中下跌,股本稳定难改观望情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683541137","title":"【券商聚焦】中信建投:医药板块前三季度经营持续改善 创新药出海、CXO等主线值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2683541137","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683541137?lang=zh_cn&edition=full","pubTime":"2026-11-13 08:44","pubTimestamp":1794530677,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券表示,2026年前三季度医药板块经营持续改善,2027年趋势有望延续。展望2027年,创新药海外临床与注册进入密集验证期,随着出海增加、战略联盟兴起,将面对更大的市场和更复杂的竞争环境,机遇和风险并存;CXO订单转化与上游需求回暖相互促进,AIDD进一步驱动需求上升。器械业绩拐点逐步显现,中药及医药商业关注经营修复,血制品与疫苗聚焦新品、整合及出海。建议围绕创新、国际化把握机会,同时建议加大关注边际改善主线。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995938","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","LU0320764599.SGD","IBBQ","MEDX","LU2097828714.EUR","09939","LU1226288170.HKD","LU0228659784.USD","LU0540923850.HKD","LU2242644610.SGD","06160","LU2097828474.EUR","IE0008369823.USD","LU0067412154.USD","IE00BZ08YT58.USD","01177","LU0823426308.USD","WX","01801","LU0650527681.SGD","CXO","601066","LU0856984785.SGD","09688","02269","BK1521","01093","LU1719994722.HKD","LU0819121731.USD","LU0140636845.USD","01877","159938","LU0516423091.SGD","LU1794554557.SGD","02616","LU1226287529.USD","06978","09995","IE00B543WZ88.USD","BK0276","02142","06185","KURE","LU1242518931.SGD","159992","LU0417516571.SGD","LNGR","HK0000165453.HKD","KCE","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681884019","title":"【券商聚焦】中信建投评26 ESMO:中国创新药持续突破,竞争与差异化并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2681884019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681884019?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:57","pubTimestamp":1793926628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指,2026年欧洲内科肿瘤学会(European Society for Medical Oncology,ESMO)中,中国创新药在多瘤种领域全面发力,众多项目从早期探索迈入III期临床或BLA/NDA阶段。国内药企已在IO双抗及多抗、ADC、小分子靶向等赛道形成多线并进格局,III期阳性终点多点开花,持续产出具备国际竞争力的临床数据,标志着中国创新药研发不断从跟随创新迈向源头创新与全球引领的新阶段,行业发展逻辑从“fast-follow”迈入“first-in-class”与“best-in-class”并行的阶段。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1995351","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1807302812.USD","BK1191","LU0455707207.USD","02142","LU0823426308.USD","LU1242518931.SGD","LU1251922891.USD","06160","KCE","LU2488822045.USD","06185","LU1242518857.USD","IE00BPRC5H50.USD","BK1583","LU0039217434.USD","LU1152091754.HKD","01877","LU0456827905.SGD","LU0708995153.HKD","LU1152091168.USD","LU2097828714.EUR","01801","LU1960683339.HKD","09926","LU0634319403.HKD","LU2242644610.SGD","02616","BK1574","LU0228659784.USD","09995","LU1188198961.HKD","09688","KURE","LU0128522744.USD","LU0315179316.USD","BK1515","LU1226287529.USD","01177","01093","LU0348783233.USD","LU0594300179.USD","LU2097828474.EUR","LU0540923850.HKD","LU1813983027.USD","LU0320764243.SGD","LU0516422952.EUR","LU0417516571.SGD","LU0348766576.USD","601066","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172682352","title":"异动解读|康希诺生物盘中上涨5.42%,生物科技板块走强叠加三季报增长支撑情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1172682352","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172682352?lang=zh_cn&edition=full","pubTime":"2026-11-05 09:43","pubTimestamp":1793842983,"startTime":"0","endTime":"0","summary":"11月5日,康希诺生物盘中上涨5.42%,报27.42港元,成交额3530.24万港元。消息面上,公司此前披露三季报,前三季度实现营收8.82亿元,同比增长27.40%;归母净利润1629.13万元,同比增长12.82%,对股价形成基本面支撑。同时,港股生物科技板块延续强势,百济神州、信达生物、康方生物、科伦博泰生物、荣昌生物涨幅居前,带动相关个股活跃。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中上涨,生物科技板块强势拉升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145579500","title":"异动解读|康希诺生物盘中上涨5.06%,生物科技板块走强叠加三季报增长支撑情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1145579500","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145579500?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:29","pubTimestamp":1793773776,"startTime":"0","endTime":"0","summary":"11月4日,康希诺生物盘中上涨5.06%,报25.74港元,成交额6438.74万港元。消息面上,公司此前披露三季报,前三季度实现营收8.82亿元,同比增长27.40%;归母净利润1629.13万元,同比增长12.82%,为股价提供基本面支撑。与此同时,当日港股生物科技板块整体走强,百济神州、康方生物、信达生物等涨幅居前,带动相关个股活跃。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。其产品主要应用于脑膜炎、百白破和肺炎领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中上涨,生物科技板块走强带动人气","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100207295","title":"康希诺生物更新10月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1100207295","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100207295?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:37","pubTimestamp":1793695034,"startTime":"0","endTime":"0","summary":"康希诺生物于2026年11月3日披露10月股份变动月报表,报告期为2026年10月。公告显示,公司法定注册股本总额为人民币247,043,801元,维持与上月一致。根据月报,康希诺生物的H股于10月末仍为132,670,900股,A股为114,372,901股,两类已发行股份总数与上月底没有变化。公司未在报告期内进行任何新增发行、回购或注销股份,并表示其在香港市场的公众持股量持续符合香港联合交易所的相关上市规则。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112259472","title":"异动解读|康希诺生物盘中下跌5.06%,保荐代表人变更叠加板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1112259472","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112259472?lang=zh_cn&edition=full","pubTime":"2026-11-03 11:41","pubTimestamp":1793677296,"startTime":"0","endTime":"0","summary":"11月3日,康希诺生物盘中下跌5.06%,报24.4港元,成交额3538.33万港元。消息面上,公司近日披露持续督导保荐代表人变更,中信证券委派王天祺接替徐峰林,与焦延延共同履职;该事项本身偏程序性,未改变公司持续督导安排。但第三季度单季净利润1701.21万元,同比下降39.08%,叠加当日生物科技板块整体偏弱,股价承压。康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物下跌,保代变更叠加板块走弱","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189042567","title":"康希诺生物变更持续督导保荐代表人","url":"https://stock-news.laohu8.com/highlight/detail?id=1189042567","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189042567?lang=zh_cn&edition=full","pubTime":"2026-11-02 18:12","pubTimestamp":1793614378,"startTime":"0","endTime":"0","summary":"2026年11月2日,康希诺生物股份公司在香港联交所发布海外监管公告,并同步于2026年11月3日在上海证券交易所披露《关于变更持续督导保荐代表人的公告》。中信证券已委派王天祺女士接替徐峰林先生,与焦延延先生共同担任公司首次公开发行股票并在科创板上市项目的持续督导保荐代表人。康希诺生物表示,本次变更后,两位保荐代表人将继续履行持续督导职责,直至中国证券监督管理委员会和上海证券交易所规定的持续督导义务结束为止。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122839011","title":"异动解读|康希诺生物盘中上涨6.1%,前三季度营收与净利双增提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1122839011","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122839011?lang=zh_cn&edition=full","pubTime":"2026-10-28 13:21","pubTimestamp":1793164895,"startTime":"0","endTime":"0","summary":"10月28日,康希诺生物盘中上涨6.1%,报29.2港元,成交额8151.65万港元。消息面上,公司披露前三季度实现营业收入8.82亿元,同比增长27.40%;归母净利润1629.13万元,同比增长12.82%,业绩增长对股价形成支撑。进一步看,第三季度单季营收3.32亿元,同比增长7.17%;前三季度非经常性损益收益6126.85万元,研发投入2.60亿元,占营收比重29.42%。此外,公司首批限制性股票归属81.13万股,并称减值及递延所得税资产减记合计影响净利3303万元。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物盘中上涨,前三季营收净利双增","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175626049","title":"康希诺生物首批限制性股票归属81.13万股 前三季度计提减值及递延税资产共影响净利3303万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175626049","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175626049?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:56","pubTimestamp":1793102171,"startTime":"0","endTime":"0","summary":"根据决议,公司将自2025年10月27日起的12个月后首个交易日起至24个月内的最后一个交易日,为85名激励对象办理限制性股票归属手续,归属数量合计811,320股,占首次授予限制性股票总量的40%。康希诺生物表示,本次限制性股票归属及部分作废事项不会对公司核心团队稳定性和激励计划的持续实施产生不利影响;本期计提的各项减值及递延所得税资产减记符合《企业会计准则》要求,客观反映了公司截至2026年9月30日的财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198128970","title":"康希诺生物(06185)发布三季报:前三季度营收8.82亿元 同比增27.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198128970","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198128970?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:31","pubTimestamp":1793100683,"startTime":"0","endTime":"0","summary":"2026年10月27日,康希诺生物股份公司披露截至2026年9月30日止九个月未经审计的第三季度报告。报告期内,公司实现营业收入8.82亿元,较上年同期增长27.40%。其中,第三季度单季实现营业收入3.32亿元,同比增加7.17%。非经常性损益方面,报告期内公司实现收益6,126.85万元,主要包括政府补助2,360.00万元、公允价值变动及处置金融资产收益2,739.78万元等。报告期内公司研发投入合计2.60亿元,同比减少5.33%,占营业收入比重为29.42%;第三季度研发投入9,369.08万元,占季度营收的28.18%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678171615","title":"康希诺生物(06185.HK)前三季度归母净利润1629.13万元 同比增长12.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678171615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678171615?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:29","pubTimestamp":1793100574,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","06185","BK1161","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678050179","title":"康希诺生物前三季度业绩增长:多产品商业化提速,平台化创新打开成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2678050179","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678050179?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:24","pubTimestamp":1793100256,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1515","BK1161","BK1191","BK1574","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141065920","title":"异动解读|康希诺生物盘中下跌5.1%,莫得纳癌症疫苗数据扰动mRNA概念情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1141065920","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141065920?lang=zh_cn&edition=full","pubTime":"2026-10-27 13:19","pubTimestamp":1793078355,"startTime":"0","endTime":"0","summary":"10月27日,康希诺生物盘中下跌5.1%,报27.52港元,成交额3876.27万港元。消息面上,市场此前对海外mRNA肿瘤疫苗临床数据抱有较高预期,但莫得纳与默克联合研发的个性化黑色素瘤疫苗三期试验数据提前泄露且未达高预期,压制了相关概念股情绪。公司已搭建mRNA开发和制备平台,并曾与德普世生物签署合作框架协议,共同开发mRNA个性化肿瘤疫苗;此前公司亦提示,海外mRNA肿瘤疫苗阶段性数据发布可能影响市场波动。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康希诺生物下跌,mRNA疫苗数据扰动情绪","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677916587","title":"港股异动 | 康希诺生物跌逾5%,莫得纳癌症疫苗试验数据泄露未达市场高预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2677916587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677916587?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:51","pubTimestamp":1792720293,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,$康希诺生物(06185)$(06185)跌逾 5%。消息面上,隔夜美股莫得纳大跌逾17%,其与默克联合研发的个性化黑色素瘤疫苗三期临床试验数据意外提前泄露,结果未达市场今年早些时候形成的高预期。今年8月,莫得纳宣布这款定制疫苗如与默克畅销药Keytruda联合使用,可显著降低这种致命肿瘤的复发风险,并具有临床意义。据悉,$康希诺(688185)$已搭建mRNA开发和制备平台,公司旗下康希诺上海此前与德普世$生物(000504)$签署合作框架协议,共同开发mRNA个性化肿瘤疫苗,由康希诺提供mRNA递送及制剂能力,德普世提供AI新抗原发现和设计平台。","market":"fut","thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511249.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"莫得纳癌症疫苗试验数据泄露未达市场高预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","HAKY","UCYB","WCBR","06185","BK4588","BK4585","BK1161","PSWD","VXUS","159646","SPAM","KCAI","CRWL","BK1574","CRWC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.111},{"period":"1month","weight":-0.2977},{"period":"3month","weight":-0.2829},{"period":"6month","weight":-0.2466},{"period":"1year","weight":-0.4955},{"period":"ytd","weight":-0.3946}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.051769},{"month":6,"riseRate":0.5,"avgChangeRate":0.015607},{"month":7,"riseRate":0.625,"avgChangeRate":0.054796},{"month":8,"riseRate":0.25,"avgChangeRate":-0.091996},{"month":9,"riseRate":0.75,"avgChangeRate":0.089616},{"month":10,"riseRate":0.375,"avgChangeRate":0.014968},{"month":11,"riseRate":0.5,"avgChangeRate":0.05503},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}